Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.